These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 33637355)

  • 1. Pancreatic ductal adenocarcinoma in the era of precision medicine.
    Zheng-Lin B; O'Reilly EM
    Semin Oncol; 2021 Feb; 48(1):19-33. PubMed ID: 33637355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moving the Needle on Precision Medicine in Pancreatic Cancer.
    O'Kane GM; Lowery MA
    J Clin Oncol; 2022 Aug; 40(24):2693-2705. PubMed ID: 35839440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma.
    Singh RR; O'Reilly EM
    Drugs; 2020 May; 80(7):647-669. PubMed ID: 32306207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications.
    Luchini C; Brosens LAA; Wood LD; Chatterjee D; Shin JI; Sciammarella C; Fiadone G; Malleo G; Salvia R; Kryklyva V; Piredda ML; Cheng L; Lawlor RT; Adsay V; Scarpa A
    Gut; 2021 Jan; 70(1):148-156. PubMed ID: 32350089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Precision Medicine and Pancreatic Cancer.
    George B
    Surg Oncol Clin N Am; 2021 Oct; 30(4):693-708. PubMed ID: 34511190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma.
    George B; Kudryashova O; Kravets A; Thalji S; Malarkannan S; Kurzrock R; Chernyavskaya E; Gusakova M; Kravchenko D; Tychinin D; Savin E; Alekseeva L; Butusova A; Bagaev A; Shin N; Brown JH; Sethi I; Wang D; Taylor B; McFall T; Kamgar M; Hall WA; Erickson B; Christians KK; Evans DB; Tsai S
    Gastroenterology; 2024 May; 166(5):859-871.e3. PubMed ID: 38280684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review.
    Singh RR; Goldberg J; Varghese AM; Yu KH; Park W; O'Reilly EM
    Cancer Treat Rev; 2019 May; 75():27-38. PubMed ID: 30927677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A special subtype: Revealing the potential intervention and great value of KRAS wildtype pancreatic cancer.
    Xu ZH; Wang WQ; Liu L; Lou WH
    Biochim Biophys Acta Rev Cancer; 2022 Jul; 1877(4):188751. PubMed ID: 35732240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting DNA damage repair pathways in pancreas cancer.
    Crowley F; Park W; O'Reilly EM
    Cancer Metastasis Rev; 2021 Sep; 40(3):891-908. PubMed ID: 34403012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.
    Singhi AD; George B; Greenbowe JR; Chung J; Suh J; Maitra A; Klempner SJ; Hendifar A; Milind JM; Golan T; Brand RE; Zureikat AH; Roy S; Schrock AB; Miller VA; Ross JS; Ali SM; Bahary N
    Gastroenterology; 2019 Jun; 156(8):2242-2253.e4. PubMed ID: 30836094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
    Moffat GT; O'Reilly EM
    Clin Adv Hematol Oncol; 2020 Mar; 18(3):168-179. PubMed ID: 32609666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
    Chandana S; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic ductal adenocarcinoma harboring microsatellite instability / DNA mismatch repair deficiency. Towards personalized medicine.
    Lupinacci RM; Bachet JB; André T; Duval A; Svrcek M
    Surg Oncol; 2019 Mar; 28():121-127. PubMed ID: 30851885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants.
    Macchini M; Centonze F; Peretti U; Orsi G; Militello AM; Valente MM; Cascinu S; Reni M
    Cancer Treat Rev; 2021 Nov; 100():102262. PubMed ID: 34418781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma.
    Shui L; Li X; Peng Y; Tian J; Li S; He D; Li A; Tian B; Li M; Gao H; An N; Yi C; Cao D
    J Transl Med; 2021 Jul; 19(1):301. PubMed ID: 34247626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next-generation therapies for pancreatic cancer.
    Buckley CW; O'Reilly EM
    Expert Rev Gastroenterol Hepatol; 2024; 18(1-3):55-72. PubMed ID: 38415709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic cancer subtypes: a roadmap for precision medicine.
    Torres C; Grippo PJ
    Ann Med; 2018 Jun; 50(4):277-287. PubMed ID: 29537309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities.
    Luchini C; Paolino G; Mattiolo P; Piredda ML; Cavaliere A; Gaule M; Melisi D; Salvia R; Malleo G; Shin JI; Cargnin S; Terrazzino S; Lawlor RT; Milella M; Scarpa A
    J Exp Clin Cancer Res; 2020 Oct; 39(1):227. PubMed ID: 33115526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma.
    Botrus G; Kosirorek H; Sonbol MB; Kusne Y; Uson Junior PLS; Borad MJ; Ahn DH; Kasi PM; Drusbosky LM; Dada H; Surapaneni PK; Starr J; Ritter A; McMillan J; Wylie N; Mody K; Bekaii-Saab TS
    Oncologist; 2021 Jul; 26(7):569-578. PubMed ID: 33555095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications.
    Zhao Z; Li X; Wang F; Xu Y; Liu S; Han Q; Yang Z; Huang W; Yin Z; Liu Q; Tan H; Ma T; Si S; Huang J; Yuan H; Li W; Liu R
    Cancer Med; 2023 May; 12(10):11672-11685. PubMed ID: 36999792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.